|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENTPD1 |
Gene summary for ENTPD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENTPD1 | Gene ID | 953 |
| Gene name | ectonucleoside triphosphate diphosphohydrolase 1 | |
| Gene Alias | ATPDase | |
| Cytomap | 10q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P49961 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 953 | ENTPD1 | male-WTA | Human | Thyroid | PTC | 5.86e-48 | 7.58e-01 | 0.1037 |
| 953 | ENTPD1 | PTC01 | Human | Thyroid | PTC | 2.77e-49 | 1.15e+00 | 0.1899 |
| 953 | ENTPD1 | PTC03 | Human | Thyroid | PTC | 1.37e-38 | 1.63e+00 | 0.1784 |
| 953 | ENTPD1 | PTC04 | Human | Thyroid | PTC | 4.23e-28 | 6.46e-01 | 0.1927 |
| 953 | ENTPD1 | PTC05 | Human | Thyroid | PTC | 1.37e-37 | 1.67e+00 | 0.2065 |
| 953 | ENTPD1 | PTC06 | Human | Thyroid | PTC | 1.19e-84 | 2.48e+00 | 0.2057 |
| 953 | ENTPD1 | PTC07 | Human | Thyroid | PTC | 1.39e-92 | 1.83e+00 | 0.2044 |
| 953 | ENTPD1 | ATC13 | Human | Thyroid | ATC | 1.90e-14 | 3.49e-01 | 0.34 |
| 953 | ENTPD1 | ATC5 | Human | Thyroid | ATC | 1.03e-13 | 3.86e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034655112 | Thyroid | PTC | nucleobase-containing compound catabolic process | 211/5968 | 407/18723 | 2.72e-17 | 2.52e-15 | 211 |
| GO:0046700111 | Thyroid | PTC | heterocycle catabolic process | 221/5968 | 445/18723 | 2.43e-15 | 1.72e-13 | 221 |
| GO:0044270111 | Thyroid | PTC | cellular nitrogen compound catabolic process | 223/5968 | 451/18723 | 3.34e-15 | 2.31e-13 | 223 |
| GO:0019439111 | Thyroid | PTC | aromatic compound catabolic process | 225/5968 | 467/18723 | 8.51e-14 | 4.71e-12 | 225 |
| GO:1901361111 | Thyroid | PTC | organic cyclic compound catabolic process | 231/5968 | 495/18723 | 2.55e-12 | 1.12e-10 | 231 |
| GO:0042060112 | Thyroid | PTC | wound healing | 190/5968 | 422/18723 | 7.72e-09 | 1.92e-07 | 190 |
| GO:000913225 | Thyroid | PTC | nucleoside diphosphate metabolic process | 64/5968 | 124/18723 | 3.80e-06 | 4.78e-05 | 64 |
| GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
| GO:003465525 | Thyroid | ATC | nucleobase-containing compound catabolic process | 217/6293 | 407/18723 | 1.20e-16 | 1.04e-14 | 217 |
| GO:004670024 | Thyroid | ATC | heterocycle catabolic process | 228/6293 | 445/18723 | 7.26e-15 | 4.50e-13 | 228 |
| GO:004427025 | Thyroid | ATC | cellular nitrogen compound catabolic process | 229/6293 | 451/18723 | 2.25e-14 | 1.27e-12 | 229 |
| GO:001943924 | Thyroid | ATC | aromatic compound catabolic process | 232/6293 | 467/18723 | 3.05e-13 | 1.44e-11 | 232 |
| GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
| GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
| GO:0006753111 | Thyroid | ATC | nucleoside phosphate metabolic process | 219/6293 | 497/18723 | 5.92e-07 | 8.29e-06 | 219 |
| GO:0009132111 | Thyroid | ATC | nucleoside diphosphate metabolic process | 64/6293 | 124/18723 | 2.59e-05 | 2.22e-04 | 64 |
| GO:000759618 | Thyroid | ATC | blood coagulation | 93/6293 | 217/18723 | 2.69e-03 | 1.23e-02 | 93 |
| GO:000759918 | Thyroid | ATC | hemostasis | 94/6293 | 222/18723 | 3.92e-03 | 1.70e-02 | 94 |
| GO:005081718 | Thyroid | ATC | coagulation | 94/6293 | 222/18723 | 3.92e-03 | 1.70e-02 | 94 |
| GO:0050878112 | Thyroid | ATC | regulation of body fluid levels | 149/6293 | 379/18723 | 1.08e-02 | 3.90e-02 | 149 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| ENTPD1 | ADORA2A | ENTPD1_ADORA2A | CD39 | Cervix | CC |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | Cervix | CC |
| ENTPD1 | ADORA2A | ENTPD1_ADORA2A | CD39 | Esophagus | ESCC |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | Esophagus | ESCC |
| ENTPD1 | ADORA2A | ENTPD1_ADORA2A | CD39 | GC | ADJ |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | HNSCC | ADJ |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | HNSCC | OSCC |
| ENTPD1 | TMIGD3 | ENTPD1_TMIGD3 | CD39 | HNSCC | OSCC |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | HNSCC | Precancer |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | Lung | AAH |
| ENTPD1 | ADORA2B | ENTPD1_ADORA2B | CD39 | Prostate | BPH |
| ENTPD1 | ADORA2A | ENTPD1_ADORA2A | CD39 | Prostate | Healthy |
| ENTPD1 | ADORA2A | ENTPD1_ADORA2A | CD39 | Skin | AK |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENTPD1 | SNV | Missense_Mutation | novel | c.555G>T | p.Glu185Asp | p.E185D | P49961 | protein_coding | tolerated(0.18) | possibly_damaging(0.6) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| ENTPD1 | SNV | Missense_Mutation | c.806G>A | p.Gly269Glu | p.G269E | P49961 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ENTPD1 | SNV | Missense_Mutation | rs775523991 | c.1161N>T | p.Glu387Asp | p.E387D | P49961 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | rs746255836 | c.1139N>C | p.Lys380Thr | p.K380T | P49961 | protein_coding | deleterious(0.04) | benign(0.108) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.1165G>T | p.Val389Phe | p.V389F | P49961 | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.389G>T | p.Arg130Met | p.R130M | P49961 | protein_coding | tolerated(0.13) | benign(0.263) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.982A>C | p.Ile328Leu | p.I328L | P49961 | protein_coding | tolerated(0.43) | benign(0.045) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.868C>A | p.Leu290Ile | p.L290I | P49961 | protein_coding | tolerated(0.4) | benign(0.125) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.341N>A | p.Gly114Asp | p.G114D | P49961 | protein_coding | tolerated(0.23) | benign(0.045) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ENTPD1 | SNV | Missense_Mutation | novel | c.1098N>T | p.Gln366His | p.Q366H | P49961 | protein_coding | tolerated(0.35) | benign(0.013) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 953 | ENTPD1 | DRUGGABLE GENOME, CELL SURFACE, ENZYME | inhibitor | 315661108 | CHEMBL608559 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |